文献速递系统性红斑狼疮

贝利尤单抗治疗系统性红斑狼疮疾病修饰作用的分子基础及早期应答的分子预测因子:血液转录组分析提示固有免疫与DNA损伤应答通路参与

Molecular basis for the disease-modifying effects of belimumab in systemic lupus erythematosus and molecular predictors of early response: blood transcriptome analysis implicates the innate immunity and DNA damage response pathways.
PubMed 文献 · Ann Rheum Dis · 2025-01-24

本研究对45例活动性SLE患者贝利尤单抗治疗基线与6个月配对的血液样本进行RNA测序,贝利尤单抗下调B细胞、I/II型干扰素、IL-6/STAT3及中性粒细胞活化相关通路,LLDAS+患者中SLE易感性特征改善更明显;神经网络模型用50个基因预测应答,交叉验证测试集特异度84%。

要点

  • 贝利尤单抗下调B细胞、I/II型干扰素、IL-6/STAT3和中性粒细胞活化相关通路。
  • 中性粒细胞脱颗粒、I型干扰素信号和细胞因子产生相关基因模块与6个月应答正相关。
  • 50个基因神经网络模型预测贝利尤单抗应答,交叉验证测试集特异度84%。

核心结论

  • 贝利尤单抗治疗改善SLE多种固有和适应性免疫失调,并可能逆转疾病特征,与药物降低活动度和预防复发的效应一致。
  • 固有免疫特征与较好改善相关,而DNA损伤应答与对BAFF抑制应答较差的疾病相关。

研究设计与样本

  • 纵向深入血液转录组研究,对活动性SLE患者贝利尤单抗治疗基线和6个月后血液进行RNA测序(n=45配对样本)。
  • 临床应答依据SLE应答指数(SRI)-4和狼疮低疾病活动状态(LLDAS)判定。
  • 采用加权基因共表达网络分析(WGCNA)揭示基因模块与性状关联,评估SLE易感性和严重性基因特征的可逆性,并使用机器学习构建应答预测模型。

主要发现

  • 贝利尤单抗诱导广泛转录组改变,下调B细胞、I/II型干扰素、IL-6/STAT3和中性粒细胞活化相关通路。
  • 上述效应在LLDAS+患者中较SRI-4+/LLDAS-应答者更明显,前者观察到SLE「易感性」特征改善。
  • 无监督分析显示富集于中性粒细胞脱颗粒、I型干扰素信号和细胞因子产生的基因模块与6个月应答正相关。
  • 使用神经网络,一组50个基因(包括CCL4L2、CARD10、MMP15和KLRC2)预测贝利尤单抗应答,交叉验证测试集特异度为84%。
  • 无应答与细胞周期检查点、PI3K/Akt/哺乳动物雷帕霉素靶蛋白和TGF-beta信号通路扰动相关。

关键数值与推荐

  • 临床应答依据SRI-4和LLDAS判定。
  • 50个基因神经网络模型预测贝利尤单抗应答的交叉验证测试集特异度为84%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Belimumab is a putative disease-modifying agent in systemic lupus erythematosus (SLE), yet the molecular underpinnings of its effects and the ability to predict early clinical response remain unexplored. To address these, we undertook a longitudinal, in-depth blood transcriptome study. METHODS: RNA-sequencing was performed in the blood of active SLE patients at baseline and following 6 months of belimumab treatment (n=45 paired samples). Clinical response was determined according to the SLE Responder Index (SRI)-4 and Lupus Low Disease Activity State (LLDAS). Weighted correlation network analysis (WGCNA) was used to uncover gene module trait associations. Reversibility of SLE susceptibility and severity gene signatures was assessed. Machine learning was used to build models predictive of response. RESULTS: Belimumab induced widespread transcriptome changes with downregulation of pathways related to B cells, type I/II interferon, IL-6/STAT3 and neutrophil activation. These effects were more pronounced among patients with LLDAS+ compared with to SRI-4+/LLDAS- response, with amelioration of the SLE 'susceptibility' signature observed in the former group. Unsupervised analysis unveiled gene modules enriched in neutrophil degranulation, type I interferon signalling and cytokine production to correlate positively with response at 6 months. Using neural networks, a set of 50 genes (including CCL4L2, CARD10, MMP15 and KLRC2) predicted response to belimumab with a cross-validated 84% specificity (test set). Lack of response was linked to perturbations of the cell cycle checkpoints, PI3K/ Akt/mammalian target of rapamycin and TGF-beta signalling pathways. CONCLUSION: Belimumab treatment ameliorates multiple innate and adaptive immunity dysregulations of SLE and may reverse the disease signature, consistent with the drug effects on reducing activity and preventing flares. Fingerprints of innate immunity correlate with robust improvement whereas DNA damage response with less responsive disease to BAFF inhibition.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Moysidou GS, Garantziotis P, Sentis G, et al. Molecular basis for the disease-modifying effects of belimumab in systemic lupus erythematosus and molecular predictors of early response: blood transcriptome analysis implicates the innate immunity and DNA damage response pathways. Ann Rheum Dis. 2025. PMID: 39919899. doi:10.1136/ard-2024-226051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。